AstraZeneca has forged a research collaboration with Boston-based BERG, a specialist in artificial intelligence for drug hunting, in the latest sign of big pharma’s interest in using supercomputers for drug discovery. The tie-up will focus on finding and evaluating novel ways of treating Parkinson’s disease and other neurological disorders. View full article: http://www.reuters.com/article/us-astrazeneca-ai-berg-idUSKCN1B81G1

While in New York City, BERG CEO and President Niven Narain dropped into the Cheddar Network studios at the New York Stock Exchange to discuss how BERG uses patient biological data and artificial intelligence to develop hypotheses in the drug-development process. Watch the interview: https://cheddar.com/videos/the-next-frontier-for-a-i-drug-research 

The Wall Street Journal’s Daniela Hernandez talks to BERG’s CEO Niven Narain about efforts to advance drug discovery through the use of AI. BERG’s Project Survival is featured as a key example of how we are working to improve the lives of patients. You can read the full article here: http://on.wsj.com/2u7QfmL

CEO Niven Narain discusses the Berg-debra of America partnership, and how patient input is critical to understanding a rare disease. The full article can be viewed here: https://www.raredr.com/news/berg-debra

BERG’s Chief Scientific Officer, Ranga Sarangarajan talks to Liz Harley at Frontline Genomics about our Phase I/II glioblastoma multiforme trials that are being guided by BERG’s AI platform. Learn more here.

Slava Akmaev recently talked to Julian Upton at PharmaExec.com about the readiness of the biotech industry to adopt Big Data and analytics approaches to their work. You can view the article here: http://www.pharmexec.com/big-data-it-crunch-time-pharma?pageID=1